Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Holding QURE?
Track your performance easily
QURE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.73 - $11.35
Previous Close$6.21
Volume837.49K
Average Volume (3M)671.05K
Market Cap
$302.45M
Enterprise Value$118.42M
Total Cash (Recent Filing)$251.63M
Total Debt (Recent Filing)$67.60M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Mar 03, 2025EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.96
Shares Outstanding48,743,140
10 Day Avg. Volume899,216
30 Day Avg. Volume671,051
Standard Deviation0.19
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)5.40
Price to Sales (P/S)11.51
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.14
Enterprise Value/Gross Profit53.46
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$18.50Price Target Upside198.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
uniQure News
PremiumCompany Announcements
uniQure Begins Phase I/IIa Trial for AMT-260 Therapy
PremiumCompany Announcements
uniQure N.V. Reports Q3 2024 Progress and Financials
PremiumCompany Announcements
uniQure Initiates Trial for Promising ALS Gene Therapy
Bulls Say, Bears Say
Bulls Say
Financial StabilityQURE ended the quarter with a cash position of $435.2MM, which is expected to fund operations through YE27.
Gene Therapy DevelopmentUniQure has dosed the first patients in trials of AMT-191 in Fabry disease and AMT-162 in ALS, and enrolled the first patient in a trial for AMT-260 in refractory temporal lobe epilepsy.
Regulatory ApprovalThe upcoming Type B meeting, enabled by QURE's Regenerative Medicine Advanced Therapy designation, will discuss the potential for an accelerated approval pathway for AMT-130.
Bears Say
Enrollment DelaysEnrollment for the AMT-260 program in refractory mesial temporal lobe epilepsy is taking longer than expected due to more restrictive inclusion criteria.
Regulatory UncertaintyThere is regulatory uncertainty surrounding the potential path for AMT-130.
Workforce ReductionQURE reduced their global workforce with the elimination of approximately 65% or 300 roles across the organization.
---
Ownership Overview
2.68% Insiders
9.78% Mutual Funds
33.84% Other Institutional Investors
49.64% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $3.73 and its highest was $11.35 in the past 12 months.
What is uniQure N.V.’s market cap?
Currently, no data Available
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Mar 03, 2025 which is in 101 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Nov 05, 2024. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.993 by $0.083.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -$0.66.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 48,743,140 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.993. Following the earnings report the stock price went up 8.993%.
Which hedge fund is a major shareholder of uniQure N.V.?
Among the largest hedge funds holding uniQure N.V.’s share is Bridger Management, LLC. It holds uniQure N.V.’s shares valued at 2M.
---
uniQure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.50 (198.15% Upside)
$18.50 (198.15% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.76%
12-Months-Change
Fundamentals
Return on Equity
-147.56%
Trailing 12-Months
Asset Growth
-25.90%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
---
QURE Stock 12 Month Forecast
Average Price Target
$18.50
▲(198.15% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Alnylam Pharma
―
Best Analysts Covering QURE
1 Year
1 Year Success Rate
18/39 ratings generated profit
1 Year Average Return
+9.49%
reiterated a buy rating 5 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +9.49% per trade.
---